These Analysts Slash Their Forecasts On FactSet Research After Q1 Results

FactSet beat Q1 expectations with revenue of $607.6M (up 6.9% Y/Y vs $600.5M consensus) and adjusted EPS of $4.51 (vs $4.37 consensus). The company reaffirmed fiscal 2026 guidance for adjusted EPS $16.90–$17.60 (consensus $17.38) and sales $2.423B–$2.448B (consensus $2.442B), guided organic ASV growth of $100M–$150M and adjusted operating margin of 34.0%–35.5%; shares jumped ~4.6% post-release while some sell-side analysts trimmed price targets (Stifel to $295, Goldman to $253).

Analysis

Market structure: FactSet (FDS) is the incumbent beneficiary — higher-than-expected Q1 revenue ($607.6M) and organic ASV guidance of $100–150M (≈4–6% of FY revenue) sustain recurring-revenue dynamics and pricing power versus smaller data resellers and terminal replacements (e.g., secondary vendors). Competitive pressure from Bloomberg/LSEG/SPGI remains a threat to share gains, but FDS’s 34–35.5% operating margin guidance signals continued cash generation that supports buybacks and product investment. Cross-asset: modest equity outperformance should tighten FDS credit spreads and keep equity-IV muted; strong USD or rising rates would be marginally negative for international bookings and discount rates on long-duration software cash flows.

Risk assessment: Tail risks include rapid AI commoditization of high-margin analytics, a major client churn or adverse data-licensing regulation — each could cut growth by >150–300 bps and compress margins by several hundred bps. Near-term (days–weeks) price action will be driven by sentiment and analyst note flow; medium term (3–12 months) hinges on ASV realization and renewal cadence; long term (12–36 months) depends on product differentiation vs. Big Tech and the pace of AI-related R&D spend. Hidden dependency: revenue sensitivity to a small number of enterprise contracts and FX; catalyst list: next ASV/renewal print, any large contract wins, and disclosures on AI product monetization.

Trade implications: Direct: consider establishing a 2–3% long position in FDS on a pullback to $270–280 with a 12-month target $320–340 and stop-loss at $250 (limits loss to ~7–8%). Options: buy a 6‑month call spread (buy $290 / sell $330) sized to replicate 1.5% delta exposure to cap cost; alternative: sell 30–60 day 5% OTM puts if willing to be assigned below $270. Pair trade: long FDS / short SPGI (ratio 1:0.5) over 6–12 months to express data-platform outperformance versus macro/exposure to cyclical index revenue. Sector: overweight FinTech/data (FDS, MSFT-adjacent analytics plays) and trim cyclical brokers/exchanges where transactional revenue is rate-sensitive.

Contrarian angles: Analysts cut PTs despite a beat — consensus may be over-focusing on multiple compression and under-appreciating recurring ASV growth; market reaction (+4.6%) looks neither extreme buy nor sell, leaving room for asymmetric upside if ASV prints at the high end. Historical parallels: FDS has previously outperformed after consecutive ASV beats while multiple re-rates lagged; unintended consequence: aggressive AI investment could compress margins near-term — if FY26 mid-point EPS falls < $17.20 or next-quarter organic ASV prints < $80M, reduce exposure by half immediately.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in FDS on a pullback to $270–280, target $320–340 within 12 months, and set a stop-loss at $250 to cap downside (~7–8%).
• Deploy a hedged options entry: buy a 6‑month FDS call spread (buy $290 / sell $330) sized to equal ~1.5% portfolio delta exposure to limit premium outlay while retaining upside to $330. Close at 50% of maximum spread gain or if FDS falls below $260.
• Implement a relative-value pair trade: long FDS / short SPGI at a 1:0.5 notional ratio over 6–12 months to express data-platform outperformance; cut the pair if FDS underperforms SPGI by >8% in 30 days or if FDS organic ASV next quarter < $80M.
• If unwilling to pay calls, sell 30–60 day 5% OTM puts on FDS for premium to establish long basis below $270; hedge position by buying the 3‑month $250 put if assigned to limit tail risk.
• Reduce exposure by 50% if management revises FY26 adjusted EPS midpoint below $17.20, or if operating margin guidance drops >200 bps vs current 34.0% mid‑point — these are actionable thresholds for material fundamental deterioration.